Claims for Patent: 7,550,143

Summary for Patent: 7,550,143

Title:	Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
Abstract:	The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity.
Inventor(s):	Chang; Chien Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Nutley, NJ)
Assignee:	IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:	11/389,358
Patent Claims:	1. A composition comprising a homodimer, each monomer of the homodimer comprising a dimerization and docking domain (DDD) attached to an antigen-binding antibody fragment, wherein the DDD consists of the sequence of SEQ ID NO:1 (DDD1) or SEQ ID NO:2 (DDD2). 2. The composition of claim 1, wherein the monomer is a fusion protein comprising the antigen-binding antibody fragment and the DDD. 3. The composition of claim 1, wherein the antigen-binding antibody fragment is chemically linked to the DDD. 4. The composition of claim 2, wherein the monomer further comprising a linker peptide between the antigen-binding antibody fragment and the DDD. 5. The composition of claim 2, wherein the antigen-binding antibody fragment comprises an Fd fragment of an antibody. 6. The composition of claim 1 wherein the antigen-binding antibody fragment is an Fab fragment. 7. The composition of claim 1, wherein the antigen-binding antibody fragment is from an antibody selected from the group consisting of a humanized antibody, a human antibody and a chimeric antibody. 8. The composition of claim 6, wherein the Fab fragment is selected from the group consisting of the Fab fragments of anti-CEA (hMN-14), anti-CD20 (hA20), anti-CD22 (hLL2), anti-CD74 (hLL1), anti-MUC-1(hPAM4), anti-CD14, anti-CD111, omalizumab, muromonab, abciximab, infliximab, and palivizumab. 9. The composition of claim 1, wherein the antigen-binding antibody fragment comprises an immunoglobulin light chain (VL-CL) or an immunoglobulin Fc domain (CH2-CH3). 10. The composition of claim 9, wherein the cysteine at the carboxyl-terminus of the CL that connects the CL to CH1 is deleted or mutated to a non-cysteine. 11. The composition of claim 9, wherein the immunoglobulin light chain or the Fc domain is selected from a human or humanized antibody. 12. The composition of claim 1, wherein the homodimer further comprises one or more effectors or carriers conjugated to the homodimer by either covalent or non-covalent linkage. 13. The composition of claim 12, wherein the effector is a diagnostic agent, a therapeutic agent, a chemotherapeutic agent, a radioisotope, an imaging agent, an anti-angiogenic agent, a cytokine, a chemokine, a growth factor, a drug, a prodrug, an enzyme, a binding molecule, a ligand for a cell surface receptor, a chelator, an immunomodulator, an oligonucleotide, a hormone, a photodetectable label, a dye, a peptide, a toxin, a contrast agent, a paramagnetic label, an ultrasound label, a pro-apoptotic agent, a liposome, a nanoparticle or a combination thereof. 14. The composition of claim 13, wherein the therapeutic agent is abrin, amantadine, amoxicillin, amphotericin B, ampicillin, aplidin, azaribine, anastrozole, azacytidine, aztreonam, azithromycin, bacitracin, bactrim, Batrafen, bifonazole, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, 10-hydroxycamptothecin, carbenicillin, caspofungin, carmustine, cefaclor, cefazolm, cephalosporins, cefepime, ceftriaxone, cefotaxime, celebrex, chlorambucil, chloramphenicol, ciprofloxacin, cisplatin, irinotecan (CPT-11), SN-38, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, diphtheria toxin, DNase I, doxorubicin, 2-pyrrolinodoxorubicine (2P-DOX), doxycycline, cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin giucuronide, ethinyl estradiol, estramustine, estrogen receptor binding agents, etoposide, etoposide glucuronide, etoposide phosphate, erythrocycline, erythromycin, flagyl, famesyl-protein transferase inhibitors, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, fluorouracil, fluoxymesterone, ganciclovir, gentamycin, gelonin, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, isoniazid, itraconazole, kanamycin, ketoconazole, L-asparaginase, leucovorin, lomustine, mechlorethamine, medroprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, minocycline, naftifine, nalidixic acid, neomycin, navelbine, nitrosurea, nystatin, onconase, oxacillin, paromomycin, penicillin, pentamidine, piperacillin-tazobactam, phenyl butyrate, prednisone, procarbazine, paclitaxel, pentostatin, pokeweed antiviral protein, PSI-341, Pseudomonas exotoxin, Pseudomonas endotoxin, raloxifene, rapLR1, ribonuclease, ricin, semustine, rifabutin, rifampin, rimantadine, streptomycin, sulfamethoxazole, sulfasalazine, Staphylococcal enterotoxin-A, streptozocin, tamoxifen, taxanes, taxol, testosterone propionate, tetracycline, thalidomide, thioguanine, thiotepa, teniposide, topotecan, transplatinum, trimethoprim sulfamethoxazole, uracil mustard, valacyclovir, vancomycin, velcade, vinblastine, vinorelbine, vincristine, zanamir, zithromycin, an antisense oligonucleotide, an interference RNA, or a combination thereof. 15. The composition of claim 13, wherein the diagnostic or therapeutic agent is selected from the group consisting of .sup.225Ac, .sup.211At, .sup.212Bi, .sup.213Bi, .sup.14C, .sup.51Cr, .sup.36Cl, .sup.45Ti, .sup.57Co, .sup.58Co, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.166Dy, .sup.152Eu, .sup.18F, .sup.67Ga, .sup.195mHg, .sup.166Ho, .sup.3H, .sup.111In, .sup.123I, .sup.124I, .sup.125I, .sup.131I, .sup.52Fe, .sup.59Fe, .sup.177Lu, .sup.191Os, .sup.212Pb, .sup.32P, .sup.33P, .sup.142Pr, .sup.195mPt, .sup.223Ra, .sup.186Re, .sup.188Re, .sup.189Re, .sup.47Sc, .sup.75Se .sup.111Ag, .sup.153Sm, .sup.89Sr, .sup.35S, .sup.161Tb, .sup.94mTc, .sup.99mTc, .sup.86Y, .sup.90Y, and .sup.89Zr. 16. The composition of claim 13, wherein the imaging agent is selected from the group consisting of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III, vanadium (II), terbium (III), dysprosium (III), holmium (III) erbium (III), lanthanum (III), gold (III), lead (II) and bismuth (III). 17. The composition of claim 13, wherein the photodetectable label is selected from the group consisting of Alexa 350, Alexa 430, AMCA, aminoacridine, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, 5-carboxy-4', 5'-dichloro-2',7'-dimethoxy fluorescein, 5-carboxy-2',4',5',7'-tetrachlorofluorescein, 5-carboxyfluorescein, 5-carboxyrhodamine, 6-carboxyrhodamine, 6-carboxytetramethyl amino, Cascade Blue, Cy2, Cy3, Cy5,6-FAM, dansyl chloride, Fluorescein, HEX, 6-JOE, NBD (7-nitrobenz-2-oxa-1,3-diazole), Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, phthalic acid, terephthalic acid, isophthalic acid, cresyl fast violet, cresyl blue violet, brilliant cresyl blue, para-aminobenzoic acid, erytlirosine, phthalocyanines, azomethines, cyanines, xanthines, succinylfluoresceins, rare earth metal cryptates, europium trisbipyridine diamine, a europium cryptate or chelate, diamine, dicyanins, La Jolla blue dye, allopycocyanin, allococyanin B, phycocyanin C, phycocyanin R, thiamine, phycoerythrocyanin, phycoerythrin R, REG, Rhodamine Green, rhodamine isothiocyanate, Rhodamine Red, ROX, TAMRA, TET, TRIT (tetramethyl rhodamine isothiol), Tetramethyirhodamine, and Texas Red. 18. The composition of claim 12, wherein the effectors or carriers are chemically cross-linked to the homodimer. 19. The composition of claim 12, wherein the homodimer is attached to two or more effectors or two or more carriers. 20. The composition of claim 19, wherein the two or more carriers or two or more effectors are either identical or different. 21. The composition of claim 12, wherein the one or more carriers comprise at least one diagnostic or therapeutic agent.

Details for Patent 7,550,143

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-04-06
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2025-04-06
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2025-04-06
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2025-04-06
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2025-04-06
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	06/20/2003		2025-04-06
Genentech, Inc.	XOLAIR	omalizumab	Injection	103976	09/28/2018		2025-04-06